Genexine, Inc.
Key Highlights
- Genexine, Inc. has a robust pipeline of innovative immunotherapeutics and next-generation therapeutics, with several products in advanced clinical stages.
- The company's acquisition of the bioPROTAC platform technology expands its capabilities in oncology, offering new potential for targeted cancer therapies.
- Genexine's strategic partnerships with global companies enhance its product development and commercialization efforts, creating significant value.
- The company's commitment to patient care and its focus on addressing critical unmet medical needs make it a compelling partner for global healthcare initiatives.
- Genexine's advanced technology platforms, including Therapeutic DNA vaccine and hyFc® long-acting technology, provide a strong foundation for future innovations in biotechnology.
About Genexine, Inc.
Genexine, Inc. is a publicly traded, clinical-stage biotechnology company based in Seoul, Korea, focused on developing and commercializing immunotherapeutics and next-generation therapeutics. The company's primary technology platforms include Therapeutic DNA vaccine, hyFc® long-acting technology, and bioPROTAC. Genexine has multiple products in clinical development, with several undergoing Phase 3 registrational trials. In 2024, the company completed a merger with EPD biotherapeutics and acquired the bioPROTAC platform technology, focusing on oncology. Genexine has established multiple partnerships with global companies to expedite product development and commercialization.
The company's proprietary pipeline includes GX-188E for head and neck cancer and cervical cancer, GX-I7 for multiple solid cancers and ARS, GX-H9 for Pediatric Growth Hormone Deficiency, and GX-E4 for CKD-induced anemia. Genexine is committed to the well-being and care of patients worldwide and is listed on the Korean exchange (KOSDAQ: 095700). For more information, visit www.genexine.com.
Founded in 1999, Genexine has been at the forefront of biotechnology innovation, leveraging its advanced technology platforms to address critical unmet medical needs. The company's strategic focus on immunotherapeutics and next-generation therapeutics positions it as a leader in the biotechnology sector.
Why Contact Genexine, Inc.?
B2B professionals should contact Genexine, Inc. for opportunities in biotechnology innovation, strategic partnerships, and access to cutting-edge therapeutics. The company's advanced technology platforms and commitment to patient care make it an attractive partner for global healthcare initiatives.
Who Should Contact Genexine, Inc. for Business?
Sales teams selling biotechnology products, recruiters seeking roles in clinical development, and partners offering technology platforms should reach out to Genexine, Inc.
Categories
- Biotechnology
- Immunotherapeutics
- Next-generation therapeutics
- Clinical development
- Therapeutic DNA vaccine
- hyFc® long-acting technology
- bioPROTAC
- Oncology
- Clinical trials
- Partnerships
More Biotechnology Companies
Frequently Asked Questions
- How many employees does Genexine, Inc. have?
- Genexine, Inc. has approximately 48 employees.
- What industry is Genexine, Inc. in?
- Genexine, Inc. operates in Biotechnology, Immunotherapy, Oncology.
- When was Genexine, Inc. founded?
- Genexine, Inc. was founded in 1999.
- What is the email format at Genexine, Inc.?
- Genexine, Inc. uses the email format first.last@genexine.com.
- Is Genexine, Inc. still active?
- Yes, Genexine, Inc. was verified as an active company on February 2, 2026. Data Surfer regularly validates company information to ensure accuracy.
- How do I sell to Genexine, Inc.?
- Research Genexine, Inc.'s priorities and goals, identify the right decision makers and champions, monitor for buying signals, and reach out at the right time with verified contact details. Learn how Data Surfer helps.
Ready to Sell to Genexine, Inc.?
Get qualified leads in 10 minutes. Research prospects, find decision makers, and monitor for the perfect moment to reach out.
Last verified: February 2, 2026
Backed by startup programs from
Connect with Genexine, Inc.